PLX.TA - Protalix BioTherapeutics, Inc.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILA
-110.00 (-7.63%)
At close: 5:24PM IST
Stock chart is not supported by your current browser
Previous Close1,441.00
Bid1,334.00 x 128000
Ask1,335.00 x 209400
Day's Range1,331.00 - 1,370.00
52 Week Range630.00 - 1,980.00
Avg. Volume57,981
Market Cap221.574M
Beta (5Y Monthly)2.88
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    Protalix BioTherapeutics Hosting Key Opinion Leader Meeting on PRX‑102 Drug Candidate for the Treatment of Fabry Disease

    Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it will host a key opinion leader (KOL) meeting on pegunigalsidase alfa, or PRX‑102, the Company's lead drug candidate for the treatment of Fabry Disease, in New York City on Monday, December 2, 2019, at 8:00 a.m. EST.

  • Associated Press

    Protalix: 1Q Earnings Snapshot

    On a per-share basis, the Carmiel, Israel-based company said it had a loss of 5 cents. The drug developer posted revenue of $10.4 million in the period. The company's shares closed at 44 cents. A year ...